Métabolic Control Cortisol Balance
Food supplement declared in France, decision dated 27 October 2026
Métabolic Control Cortisol Balance is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- LES TROIS CHENES
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2 gélules par jour
- Directions for use
- Prendre 2 gélules par jour le soir au dîner avec un verre d’eau
- Intended populations
- General population, Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Weight management / Slimming, Mood
Declaration 368768, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Nigella sativa L. | Graine (huile) | Pression à froid | 300 mg |
| Cichorium intybus L. | Racine | Poudre (de plantes séchées ou broyées) | 140 mg |
| Sedum roseum (L.) Scop. | Racine | Extrait sec hydroalcoolique | 60 mg |
| Capsicum annuum L. | Fruit | Extrait sec hydroalcoolique | 22.5 mg |
Substances
| Name | Per day |
|---|---|
| tryptophane | 100 mg |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| Bisglycinate de magnésium | Magnésium | 250 mg | 300 mg |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
Additives
E470b
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Regulatory points
- Conditions légales
Nigella sativa L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les enfants, adolescents, femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Sedum roseum (L.) Scop.
Read the warning, when it applies and the studies cited
RHODIOLA - RHODIOLA ROSEA
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024: 20 March 2024 EMA/HMPC/24177/2023 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Rhodiola rosea L., rhizoma et radix Final - Revision 1. Amsterdam (NL): European Medicines Agency, Science Medicines Health. [Accessed 2025 January 21]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-rhodiola-rosea-l-rhizoma-et-radix-revision-1_en.pdf
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking antidepressant medication, hormone replacement therapy (HRT) or birth control medication (HC 2018; Iovieno et al. 2011; Olsson et al. 2009; Brown et al. 2002).
Sources cited by Health Canada (4)
- Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
- HC 2018: Health Canada. Canada Vigilance Adverse Reaction Online Database. Ottawa (ON): Marketed Health Products Directorate, Health Canada. [Accessed 2025 January 21]. Available from: https://cvp-pcv.hc-sc.gc.ca/arq-rei/index-eng.jsp
- Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
- SC 2018: Santé Canada. Base de données en ligne des effets indésirables de Canada Vigilance. Ottawa (ON): Direction des produits de santé commercialisés, Santé Canada. [Consulté le 21 janvier 2025]. Disponible à : https://cvp-pcv.hc-sc.gc.ca/arq-rei/switchlocale.do?lang=fr&url=t.search.recherche
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you have bipolar disorder or bipolar spectrum disorder (Iovieno et al. 2011; Winston and Maimes 2007; Brown et al. 2002).
Sources cited by Health Canada (3)
- Brown RP, Gerbarg PL, Ramazanov Z. Rhodiola rosea: A Phytomedicinal Overview. HerbalGram 2002;56:40-52.
- Iovieno, N., Dalton, ED., Fava, M., Mischoulon, D. Second-tier natural antidepressants: review and critique. Journal of Affective Disorders 2011;130(3): 343-357.
- Winston D, Maimes S. Adaptogens: Herbs for Strength, Stamina, and Stress Relief. Rochester (VT): Healing Arts Press, 2007.
Known adverse reactions
Stop use if you experience irritability or insomnia (Pizzorno and Murray 2006; Kelly 2001).
Sources cited by Health Canada (2)
- Kelly GS. Rhodiola rosea: A Possible Plant Adaptogen. Alternative Medicine Review 2001;6(3): 293-302. PubMed Review article
- Pizzorno JE, Murray MT, editors. Textbook of Natural Medicine. 3rd edition, volume 1. St. Louis (MI): Churchill Livingstone Elsevier; 2006.
- Capsicum annuum L.
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.